Viewing Study NCT03221634


Ignite Creation Date: 2025-12-25 @ 2:24 AM
Ignite Modification Date: 2026-02-28 @ 10:35 PM
Study NCT ID: NCT03221634
Status: WITHDRAWN
Last Update Posted: 2019-03-25
First Post: 2017-07-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module